Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Other Gross PP&E Adjustments (2016 - 2026)

Akebia Therapeutics has reported Other Gross PP&E Adjustments over the past 11 years, most recently at -$5.3 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 45.6% to -$5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 45.6% year-over-year, with the annual reading at -$5.3 million for FY2025, 45.6% up from the prior year.
  • Other Gross PP&E Adjustments was -$5.3 million for Q4 2025 at Akebia Therapeutics, up from -$6.4 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at -$5.3 million in Q4 2025 and troughed at -$32.6 million in Q1 2022.
  • The 5-year median for Other Gross PP&E Adjustments is -$16.5 million (2023), against an average of -$18.4 million.
  • Year-over-year, Other Gross PP&E Adjustments plummeted 30.81% in 2022 and then surged 55.78% in 2023.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$28.6 million in 2021, then increased by 19.86% to -$22.9 million in 2022, then rose by 18.93% to -$18.6 million in 2023, then surged by 48.01% to -$9.7 million in 2024, then surged by 45.6% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Gross PP&E Adjustments are -$5.3 million (Q4 2025), -$6.4 million (Q3 2025), and -$7.6 million (Q2 2025).